Indications |
Oral Male hypogonadism Adult: Androgen deficiency: 10-50 mg daily . Postpubertal cryptorchidism: 30 mg daily. Oral Menopausal vasomotor symptoms Adult: For short term treatment: 1.25-2.5 mg daily in combination with estrogen for 21 days or 28-day cycle. Oral Metastatic breast carcinoma in postmenopausal women Adult: 50-200 mg daily. Buccal Male hypogonadism Adult: Androgen deficiency: 5-25 mg daily. Postpubertal cryptorchidism: 15 mg daily. Buccal Metastatic breast carcinoma in postmenopausal women Adult: 25-100 daily. Oral Prophylaxis of postpartum breast pain and engorgement Adult: 80 mg daily for 3-5 days after childbirth. Buccal Prophylaxis of postpartum breast pain and engorgement Adult: 40 mg daily for 3-5 days after childbirth. |
Contraindications |
In males, known or suspected carcinoma of the breast or prostate. Pregnancy. Severe hepatic impairment. |
Warnings / Precautions |
Hepatic impairment; monitor liver function periodically. Breast cancer in women; may cause hypercalcaemia. DM. Conditions influenced by oedema (e.g. CV disease, migraine, seizure disorder, renal impairment). Elderly. May accelerate bone maturation without compensatory gain in linear growth in children. Monitor for signs of virilisation in women (discontinue if mild virilisation develops) and development of priapism or excessive sexual stimulation in men. Lactation. |
Adverse Reactions |
Oedema; headache, anxiety, depression; acne, male-pattern baldness, seborrhoea; hypercalcaemia, hypercholesterolaemia; GI irritation, nausea, vomiting; leucopenia, polycythemia; hypersensitivity reactions. Male: Virilism, priapism, prostatic hyperplasia, prostatic carcinoma, impotence, testicular atrophy, gynaecomastia. Female: Virilism, menstrual irregularities (amenorrhoea), breast soreness, hirsutism (increase in pubic hair growth), atrophy. Potentially Fatal: Cholestatic hepatitis with jaundice, peliosis hepatis, hepatic neoplasms. |
Overdose Reactions |
Abnormal LFTs. |
Drug Interactions |
May increase effects of oral anticoagulants and hypoglycaemic agents. Potentially Fatal: May increase risk of ciclosporin toxicity. See Below for More methyltestosterone Drug Interactions |
Lab Interactions |
May decrease thyroxine-binding globulin concentrations. |
Mechanism of Actions |
Methyltestosterone is a synthetic androgenic anabolic steroid hormone. It promotes growth and development of male sex organs by stimulating receptors in organs and tissues, and maintains secondary sex characteristics in androgen-deficient men. Absorption: Absorbed from the GI tract and from the oral mucosa. Metabolism: Hepatic. Excretion: Via urine. |
ATC Classification |
G03BA02 - methyltestosterone ; Belongs to the class of 3-oxoandrosten (4) derivative androgens used in androgenic hormone preparations. G03EK01 - methyltestosterone ; Belongs to the class of androgens and female sex hormones in combination. |
Available As |
|
Methyl Testosterone
Post Review about Methyl Testosterone Click here to cancel reply.
Methyl Testosterone Containing Brands
Methyl Testosterone is used in following diseases
Drug - Drug Interactions of Methyl Testosterone
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.